Deeks Steven G, Lu Jing, Hoh Rebecca, Neilands Torsten B, Beatty George, Huang Wei, Liegler Teri, Hunt Peter, Martin Jeffrey N, Kuritzkes Daniel R
University of California, San Francisco, San Francisco, CA 94110, USA.
J Infect Dis. 2007 Feb 1;195(3):387-91. doi: 10.1086/510531. Epub 2006 Dec 21.
Many antiretroviral drugs continue to exert an anti-human immunodeficiency virus (HIV) benefit in the presence of drug resistance mutations. The degree to which enfuvirtide exerts continued antiviral activity in the presence of incomplete viral suppression has not been defined. To address this question, 25 subjects interrupted enfuvirtide while remaining on a stable background regimen. Enfuvirtide interruption was associated with an immediate but limited increase in plasma HIV-1 RNA levels. Enfuvirtide resistance waned rapidly in the absence of drug pressure and was no longer detectable by week 16 in most individuals. These data indicate that enfuvirtide has measurable antiviral activity in the setting of incomplete viral suppression. Although enfuvirtide resistance mutations are associated with significant fitness defects in vivo, the clinical significance of these mutations remains undefined.
许多抗逆转录病毒药物在存在耐药性突变的情况下仍能继续发挥抗人类免疫缺陷病毒（HIV）的作用。在病毒抑制不完全的情况下，恩夫韦肽发挥持续抗病毒活性的程度尚未明确。为解决这一问题，25名受试者在维持稳定背景治疗方案的同时中断了恩夫韦肽治疗。中断恩夫韦肽治疗与血浆HIV-1 RNA水平立即但有限的升高有关。在没有药物压力的情况下，恩夫韦肽耐药性迅速减弱，大多数个体在第16周时已无法检测到。这些数据表明，在病毒抑制不完全的情况下，恩夫韦肽具有可测量的抗病毒活性。虽然恩夫韦肽耐药性突变在体内与显著的适应性缺陷相关，但这些突变的临床意义仍不明确。
